Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from ZyVersa Therapeutics ( (ZVSA) ) is now available.
ZyVersa Therapeutics, Inc. is facing a significant change in its stock market status as the Nasdaq Stock Market has announced the delisting of the company’s common stock, effective ten days after the filing of Form 25 with the SEC. This follows the suspension of trading on the Nasdaq Capital Market on July 17, 2025, due to non-compliance with minimum bid price requirements, with the stock continuing to trade on the OTCQB Venture Market under the symbol ‘ZVSA’.
The most recent analyst rating on (ZVSA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ZyVersa Therapeutics stock, see the ZVSA Stock Forecast page.
Spark’s Take on ZVSA Stock
According to Spark, TipRanks’ AI Analyst, ZVSA is a Underperform.
ZyVersa Therapeutics faces significant financial challenges with no revenue and ongoing losses. Technical indicators show bearish momentum, and the negative P/E ratio suggests overvaluation concerns. The lack of dividend yield further limits investment appeal.
To see Spark’s full report on ZVSA stock, click here.
More about ZyVersa Therapeutics
Average Trading Volume: 4,068,615
Technical Sentiment Signal: Sell
Current Market Cap: $1.34M
See more data about ZVSA stock on TipRanks’ Stock Analysis page.